鼻内纳洛酮重复给药策略与芬太尼过量:基于模拟的随机临床试验
该非盲交叉随机临床试验在健康受试者中比较三种鼻内纳洛酮重复给药策略,主要终点为预设时间点纳洛酮血浆浓度,次要终点为模拟芬太尼过量后脑缺氧时间。21例受试者中18例(86%)完成试验。与0、2.5分钟各1剂相比,0、2.5、5、7.5分钟各1剂显著提高10分钟血浆浓度(7.95 vs 4.42 ng/mL;几何均值比1.95 [单侧97.8% CI, 1.28-∞]),0、2.5分钟各2剂显著提高4.5分钟血浆浓度(2.24 vs 1.23 ng/mL;几何均值比1.98 [单侧97.8% CI, 1.03-∞])。模拟芬太尼2.97 mg静脉推注后中位脑缺氧时间三组分别为4.5、4.5、3.7分钟。作者结论认为需进一步研究确定社区最佳纳洛酮剂量。
要点
- 健康受试者中,0、2.5、5、7.5分钟各1剂鼻内纳洛酮较0、2.5分钟各1剂显著提高10分钟血浆浓度(7.95 vs 4.42 ng/mL;几何均值比1.95 [单侧97.8% CI, 1.28-∞])。
- 0、2.5分钟各2剂较0、2.5分钟各1剂显著提高4.5分钟血浆浓度(2.24 vs 1.23 ng/mL;几何均值比1.98 [单侧97.8% CI, 1.03-∞])。
- 模拟芬太尼2.97 mg静脉推注后中位脑缺氧时间:0、2.5分钟各1剂为4.5分钟(IQR, 2.1-∞分钟),0、2.5、5、7.5分钟各1剂为4.5分钟(IQR, 2.1-∞分钟),0、2.5分钟各2剂为3.7分钟(IQR, 1.5-∞分钟)。
- 未报告药物相关严重不良事件。
- 作者认为需进一步研究以确定社区环境中的最佳纳洛酮剂量。
适用人群与场景
- 健康受试者,年龄18至55岁,不吸烟,酒精或滥用药物检测阴性;在临床药理学单位(Spaulding Clinical Research,West Bend,Wisconsin)入组。
- 研究于2021年3月进行;数据分析于2021年10月至2023年5月进行。
研究设计与关键结果
- 研究类型:非盲交叉随机临床试验,纳入21例健康受试者,18例(86%)完成试验;中位年龄34岁(IQR, 27-50岁),男性11例(52%)。
- 干预:纳洛酮4 mg/0.1 mL鼻内给药,方案为0、2.5、5、7.5分钟各1剂(试验组),0、2.5分钟各2剂(试验组),0、2.5分钟各1剂(参照组)。
- 主要终点:与0、2.5分钟各1剂相比,0、2.5、5、7.5分钟各1剂显著提高10分钟纳洛酮血浆浓度(7.95 vs 4.42 ng/mL;几何均值比1.95 [单侧97.8% CI, 1.28-∞]);0、2.5分钟各2剂显著提高4.5分钟血浆浓度(2.24 vs 1.23 ng/mL;几何均值比1.98 [单侧97.8% CI, 1.03-∞])。
- 次要终点:模拟芬太尼2.97 mg静脉推注后中位脑缺氧时间:0、2.5分钟各1剂为4.5分钟(IQR, 2.1-∞分钟),0、2.5、5、7.5分钟各1剂为4.5分钟(IQR, 2.1-∞分钟),0、2.5分钟各2剂为3.7分钟(IQR, 1.5-∞分钟)。
- 不良事件:未报告药物相关严重不良事件。
证据类型、等级与局限
- 证据类型:非盲交叉随机临床试验(健康受试者)。
- 局限:作者指出需进一步研究以确定社区环境中的最佳纳洛酮剂量。
对床旁实践的改变
- 在健康受试者中,0、2.5、5、7.5分钟各1剂鼻内纳洛酮较0、2.5分钟各1剂提高10分钟血浆浓度;0、2.5分钟各2剂较0、2.5分钟各1剂提高4.5分钟血浆浓度。
- 模拟芬太尼2.97 mg静脉推注后脑缺氧时间在三组间数值接近,作者认为需进一步研究确定社区最佳剂量。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Questions have emerged as to whether standard intranasal naloxone dosing recommendations (ie, 1 dose with readministration every 2-3 minutes if needed) are adequate in the era of illicitly manufactured fentanyl and its derivatives (hereinafter, fentanyl).
OBJECTIVE: To compare naloxone plasma concentrations between different intranasal naloxone repeat dosing strategies and to estimate their effect on fentanyl overdose.
DESIGN, SETTING, AND PARTICIPANTS: This unblinded crossover randomized clinical trial was conducted with healthy participants in a clinical pharmacology unit (Spaulding Clinical Research, West Bend, Wisconsin) in March 2021. Inclusion criteria included age 18 to 55 years, nonsmoking status, and negative test results for the presence of alcohol or drugs of abuse. Data analysis was performed from October 2021 to May 2023.
INTERVENTION: Naloxone administered as 1 dose (4 mg/0.1 mL) at 0, 2.5, 5, and 7.5 minutes (test), 2 doses at 0 and 2.5 minutes (test), and 1 dose at 0 and 2.5 minutes (reference).
MAIN OUTCOMES AND MEASURES: The primary outcome was the first prespecified time with higher naloxone plasma concentration. The secondary outcome was estimated brain hypoxia time following simulated fentanyl overdoses using a physiologic pharmacokinetic-pharmacodynamic model. Naloxone concentrations were compared using paired tests at 3 prespecified times across the 3 groups, and simulation results were summarized using descriptive statistics.
RESULTS: This study included 21 participants, and 18 (86%) completed the trial. The median participant age was 34 years (IQR, 27-50 years), and slightly more than half of participants were men (11 [52%]). Compared with 1 naloxone dose at 0 and 2.5 minutes, 1 dose at 0, 2.5, 5, and 7.5 minutes significantly increased naloxone plasma concentration at 10 minutes (7.95 vs 4.42 ng/mL; geometric mean ratio, 1.95 [1-sided 97.8% CI, 1.28-∞]), whereas 2 doses at 0 and 2.5 minutes significantly increased the plasma concentration at 4.5 minutes (2.24 vs 1.23 ng/mL; geometric mean ratio, 1.98 [1-sided 97.8% CI, 1.03-∞]). No drug-related serious adverse events were reported. The median brain hypoxia time after a simulated fentanyl 2.97-mg intravenous bolus was 4.5 minutes (IQR, 2.1-∞ minutes) with 1 naloxone dose at 0 and 2.5 minutes, 4.5 minutes (IQR, 2.1-∞ minutes) with 1 naloxone dose at 0, 2.5, 5, and 7.5 minutes, and 3.7 minutes (IQR, 1.5-∞ minutes) with 2 naloxone doses at 0 and 2.5 minutes.
CONCLUSIONS AND RELEVANCE: In this clinical trial with healthy participants, compared with 1 intranasal naloxone dose administered at 0 and 2.5 minutes, 1 dose at 0, 2.5, 5, and 7.5 minutes significantly increased naloxone plasma concentration at 10 minutes, whereas 2 doses at 0 and 2.5 minutes significantly increased naloxone plasma concentration at 4.5 minutes. Additional research is needed to determine optimal naloxone dosing in the community setting.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04764630.
参考来源
- Strauss DG, Li Z, Chaturbedi A, et al. Intranasal Naloxone Repeat Dosing Strategies and Fentanyl Overdose: A Simulation-Based Randomized Clinical Trial. JAMA Netw Open. 2024. PMID: 38261323. doi:10.1001/jamanetworkopen.2023.51839
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。